

Haematologica
HAEMATOL/2017/165845
Version 3

Prolonged versus standard native *E. coli* asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951

Veerle Mondelaers, Stefan Suciu, Barbara De Moerloose, Alina Ferster, Françoise Mazingue, Geneviève Plat, Karima Yakouben, Anne Uyttebroeck, Patrick Lutz, Vitor Costa, Nicolas Sirvent, Emmanuel Plouvier, Martine Munzer, Maryline Poirée, Odile Minckes, Frédéric Millot, Dominique Plantaz, Philip Maes, Claire Hoyoux, Hélène Cave', Pierre Rohrlich, Yves Bertrand, and Yves Benoit

Disclosures: 1. The authors acknowledge support from vzw. Kinderkankerfonds (a non-profit childhood cancer foundation under Belgian law); Vlaamse Liga Tegen Kanker; the Belgian Program of Interuniversity Poles of Attraction (36509110 to FS); and the EORTC Cancer Research Fund. 2. Conflict-of-interest disclosure: V.M. invited speaker and membership on an advisory board for Jazz Pharma since 2015. The other authors declare no conflicts-of-interest.

Contributions: Contribution: V.M. checked the data and wrote the manuscript; S.S. was the study statistician and analyzed the data and designed the figures and tables; Y. Bertrand and Y. Benoit are former and P.R. present chairmen of the EORTC-CLG, they planned and coordinated the study; H.C. coordinated biological studies; V.M., B.D.M., A.F., F. Mazingue, G.P., K.Y., A.U., P.L., V.C., N.S., M.M., M.P., P.B., F. Millot, D.P., P.M., C.H., Y. Bertrand and Y. Benoit included patients in the trial and provided clinical data. All authors participated in study supervision, participated in data interpretation, and critically reviewed the manuscript.